Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) and Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) today announced that Royalty Pharma has acquired Dicerna’s royalty interest in OXLUMO™ (lumasiran) for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments. OXLUMO, which has been approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of primary hyperoxaluria (PH) type 1, is marketed by Alnylam Pharmaceuticals, Inc. (“Alnylam”).
[…]
Gibson Dunn, Jones Day and Maiwald acted as legal advisors to Royalty Pharma. J. Wood Capital Advisors acted as Dicerna’s sole financial advisor and Latham & Watkins acted as legal advisor to Dicerna on the transaction.
This text is a press release from Royalty Pharma. The full text version of the article can be found here: Royalty Pharma Acquires Oxlumo™ Royalty Interest from Dicerna for Up to $240 Million
